San Diego, CA, United States of America

Martin Hosking

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Martin Hosking: Innovator in Cancer Therapeutics

Introduction

Martin Hosking is a prominent inventor based in San Diego, CA (US). He has made significant contributions to the field of cancer therapeutics, holding a total of 3 patents. His work focuses on developing innovative methods and compositions for enhancing therapeutic effects in cancer treatment.

Latest Patents

Among his latest patents is "Cells having solid tumor targeting backbone and use thereof." This patent provides methods and compositions for obtaining functionally enhanced derivative effector cells derived from directed differentiation of genomically engineered iPSCs. It also includes derivative cells with stable and functional genome editing that deliver improved therapeutic effects. Another notable patent is "Chimeric antigen receptor for tumor targeting," which presents chimeric antigen receptors (CAR) specific to selected tumor antigens, along with structural designs and functional profiles of the CAR candidates.

Career Highlights

Martin has worked with several notable companies in the biotechnology sector, including Fate Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to contribute to groundbreaking advancements in cancer treatment.

Collaborations

Throughout his career, Martin has collaborated with esteemed colleagues such as Bahram Valamehr and Tom Tong Lee. These partnerships have further enriched his research and development efforts in the field.

Conclusion

Martin Hosking is a key figure in the innovation of cancer therapeutics, with a focus on enhancing treatment efficacy through advanced cellular technologies. His contributions continue to impact the landscape of cancer research and therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…